Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 30, 2025

3 Non-AI Stocks to Buy: MRK, UPS, CVX

View original at nasdaq.com
3 Non-AI Stocks to Buy: MRK, UPS, CVX In this podcast, Motley Fool analysts Anthony Schiavone, Karl Thiel, and Tim Beyers discuss: Merk's $9.2 billion acquisition of Cidara Therapeutics.Earnings news from UPS and Chevron.Other investing tidbits…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stock Advisor's total average return is 1,004% compared to 194% for S&P 500

    80% confidence

  • Merck is not paying an outrageous amount for Cidara given the drug's broader potential and platform applications

    80% confidence

  • $1,000 invested in Nvidia on April 15, 2005 would be worth $1,084,986

    80% confidence

  • Merck is attractively priced relative to rest of market

    80% confidence

  • Hasbro should not increase dividend in 2026, capital has better uses

    80% confidence

  • Wabtec will increase dividend in 2026 based on low 12% payout ratio and stated goal

    80% confidence

  • $1,000 invested in Netflix on December 17, 2004 would be worth $580,171

    80% confidence

  • UPS is a buy with 7% dividend yield potentially enough to beat market over 5-10 years

    80% confidence

  • UPS is firmly in a turnaround and this quarter shows turnaround is in early stages of turning

    80% confidence

  • CF Industries unlikely to increase dividend in 2026 due to preference for buybacks and commodity price uncertainty

    80% confidence

  • Chevron is a buy with 4.3% yield and expected 10% annual free cash flow growth through 2030 representing double-digit expected return

    80% confidence

  • UPS expects to reduce expenses by $3.5 billion in 2025

    80% confidence

  • Chevron expects to return $10-20 billion annually to shareholders through 2030

    80% confidence

  • UPS's better, not bigger strategy is progressing based on improved revenue per piece despite volume decline

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
3 Non-AI Stocks to Buy: MRK, UPS, CVX — Source | Via News | Via News